Raymond James initiated coverage on shares of Trevi Therapeutics (NASDAQ:TRVI - Free Report) in a research note issued to investors on Friday, Marketbeat.com reports. The brokerage issued an outperform rating and a $9.00 price objective on the stock.
TRVI has been the topic of a number of other reports. Needham & Company LLC reaffirmed a buy rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, May 8th. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a strong-buy rating in a research note on Monday, August 19th. Finally, Rodman & Renshaw began coverage on shares of Trevi Therapeutics in a research note on Thursday, June 13th. They issued a buy rating and a $7.00 price target on the stock. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of Buy and a consensus price target of $7.80.
Check Out Our Latest Research Report on Trevi Therapeutics
Trevi Therapeutics Stock Up 8.6 %
Shares of TRVI traded up $0.25 during mid-day trading on Friday, reaching $3.16. The company's stock had a trading volume of 289,419 shares, compared to its average volume of 236,473. The company has a market cap of $229.38 million, a price-to-earnings ratio of -9.29 and a beta of 1.00. The business has a fifty day moving average of $2.84 and a 200 day moving average of $2.84. Trevi Therapeutics has a 1 year low of $0.97 and a 1 year high of $4.00.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same period in the previous year, the firm earned ($0.07) earnings per share. On average, analysts predict that Trevi Therapeutics will post -0.46 earnings per share for the current year.
Insider Buying and Selling at Trevi Therapeutics
In other news, insider Thomas Sciascia sold 18,660 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the transaction, the insider now owns 220,315 shares in the company, valued at approximately $608,069.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 23,315 shares of company stock worth $65,123 over the last ninety days. 24.37% of the stock is currently owned by insiders.
Institutional Trading of Trevi Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD acquired a new stake in shares of Trevi Therapeutics in the first quarter worth $47,000. Hsbc Holdings PLC acquired a new position in Trevi Therapeutics during the 2nd quarter worth $61,000. The Manufacturers Life Insurance Company lifted its position in Trevi Therapeutics by 87.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company's stock worth $73,000 after acquiring an additional 11,450 shares during the last quarter. American Century Companies Inc. boosted its holdings in Trevi Therapeutics by 17.1% during the second quarter. American Century Companies Inc. now owns 54,108 shares of the company's stock valued at $161,000 after acquiring an additional 7,902 shares during the period. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of Trevi Therapeutics in the first quarter valued at about $208,000. Institutional investors and hedge funds own 95.76% of the company's stock.
Trevi Therapeutics Company Profile
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Further Reading
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
